Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (Q3)Oct 31, 2025 | (Q2)Jul 31, 2025 | (Q1)Apr 30, 2025 | (FY)Jan 31, 2025 | (Q4)Jan 31, 2025 | (Q3)Oct 31, 2024 | (Q2)Jul 31, 2024 | (Q1)Apr 30, 2024 | (FY)Jan 31, 2024 | (Q4)Jan 31, 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | 119.65%34.61K | 89.66%-29.41K | 103.88%31.2K | 59.89%-1.3M | -533.75%-35.82K | 35.51%-176.09K | 68.92%-284.56K | 61.01%-804.51K | 28.07%-3.24M | 102.71%8.26K |
| Net income from continuing operations | 61.14%-333.83K | 57.28%-413.78K | 7.80%-760.83K | 21.91%-4.07M | -86.54%-1.42M | 26.46%-858.98K | 38.62%-968.61K | 51.71%-825.24K | 12.75%-5.22M | 61.06%-761.66K |
| Operating gains losses | ---- | ---- | ---- | --20.47K | ---- | ---- | ---- | ---- | ---- | ---- |
| Depreciation and amortization | -90.91%2.68K | -90.00%2.68K | 9.68%29.4K | 21.28%113.24K | 13.20%30.12K | 7.63%29.51K | 29.84%26.81K | 43.34%26.81K | 85.69%93.37K | 86.20%26.61K |
| Remuneration paid in stock | --0 | --0 | -84.89%12.76K | -8.14%519K | 177.61%271.14K | -42.27%60.74K | -43.99%102.7K | -52.78%84.42K | 43.79%565.01K | -45.95%97.67K |
| Other non cashItems | -94.55%2.77K | -110.42%-6.31K | 246.31%81.83K | 143.61%123.51K | 95.68%-11.61K | -83.32%50.91K | 723.17%60.57K | 258.03%23.63K | 389.93%50.7K | -1,380.72%-268.41K |
| Change In working capital | -32.99%362.99K | -21.45%388K | 685.34%668.04K | 57.95%2M | 17.60%1.07M | 18.47%541.73K | 9.45%493.98K | 79.57%-114.13K | 24.43%1.26M | -36.94%914.06K |
| -Change in receivables | -100.01%-1 | 65.40%10.88K | -354.72%-2.89K | -98.91%3.78K | -113.14%-20.39K | -39.76%18.23K | -96.91%6.58K | 98.75%-636 | 272.67%347.23K | -51.78%155.19K |
| -Change in prepaid assets | 1,532.44%80.92K | 51.37%-37.76K | 95.52%-347 | -160.63%-40.38K | -23.09%40.06K | -36.51%4.96K | -1,474.91%-77.64K | -166.62%-7.75K | 212.57%66.6K | 77.75%52.09K |
| -Change in payables and accrued expense | -45.60%282.07K | -26.58%414.88K | 734.84%671.28K | 139.13%2.03M | 49.30%1.06M | 23.70%518.54K | 131.94%565.05K | 79.64%-105.74K | -33.38%850.2K | -35.65%706.78K |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | 119.65%34.61K | 89.66%-29.41K | 103.88%31.2K | 59.89%-1.3M | -533.75%-35.82K | 35.51%-176.09K | 68.92%-284.56K | 61.01%-804.51K | 28.07%-3.24M | 102.50%8.26K |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 144.54%18.42K | 13.29%18.42K | 0 | 0 | 0 | 91.81%-41.35K | 103.58%16.26K | |||
| Net PPE purchase and sale | ---- | ---- | ---- | 144.54%18.42K | 13.29%18.42K | --0 | --0 | --0 | 48.06%-41.35K | 164.67%16.26K |
| Net investment purchase and sale | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --0 | ---- |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | ---- | ---- | ---- | 144.54%18.42K | 13.29%18.42K | --0 | --0 | --0 | 91.81%-41.35K | 103.58%16.26K |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | -291.46%-20.78K | 0 | -102.10%-16.93K | -59.97%1.28M | 11.01%-23.51K | -93.72%10.86K | 2,523.37%489.74K | -73.83%805.19K | -18.74%3.2M | -109.36%-26.42K |
| Net issuance payments of debt | -290.78%-35.32K | --0 | -101.25%-10.39K | 623.65%792.65K | -17.98%-31.17K | -89.30%18.51K | -33.79%-27.04K | 5,055.63%832.35K | 272.60%109.54K | -57.31%-26.42K |
| Net common stock issuance | ---- | ---- | ---- | --0 | --0 | --0 | --0 | --0 | -39.39%2.6M | --0 |
| Proceeds from stock option exercised by employees | --0 | --0 | --8K | -13.87%516.78K | --1.59K | ---1.59K | --516.78K | --0 | 100.00%600K | --0 |
| Net other financing activities | ---- | --0 | 46.47%-14.54K | 75.61%-27.16K | --6.07K | ---6.07K | ---1 | 75.61%-27.16K | 81.22%-111.35K | --0 |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | -291.46%-20.78K | --0 | -102.10%-16.93K | -59.97%1.28M | 11.01%-23.51K | -93.72%10.86K | 2,523.37%489.74K | -73.83%805.19K | -18.74%3.2M | -109.36%-26.42K |
| Net cash flow | ||||||||||
| Beginning cash position | -100.08%-167 | 799.34%14.97K | -28.99%703 | -98.81%990 | 1,336.38%41.61K | 79.78%206.85K | -99.84%1.67K | -98.81%990 | -92.81%83.1K | -99.50%2.9K |
| Current changes in cash | 108.37%13.83K | -114.33%-29.41K | 2,014.22%14.27K | 99.65%-287 | -2,045.20%-40.91K | -47.32%-165.23K | 121.66%205.18K | -99.93%675 | 92.35%-82.11K | 99.62%-1.91K |
| End cash Position | -101.47%-613 | -100.08%-167 | 799.34%14.97K | -28.99%703 | -28.99%703 | 1,336.38%41.61K | 79.78%206.85K | -99.84%1.67K | -98.81%990 | -98.81%990 |
| Free cash from | 119.65%34.61K | 89.66%-29.41K | 103.88%31.2K | 60.40%-1.3M | -246.09%-35.82K | 38.24%-176.09K | 69.30%-284.56K | 61.64%-804.51K | 28.42%-3.29M | 106.91%24.52K |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.